Awaiting development: Guidance and quality standards

Showing 61 to 70 of 363

Guidance and quality standards awaiting development
Title	Type
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]	Technology appraisal guidance
Camlipixant for treating refractory or unexplained chronic cough [TSID12072]	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]	Technology appraisal guidance
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]	Technology appraisal guidance
Capsule sponge tech for oesophageal cancer	Health technology evaluation
Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]	Technology appraisal guidance
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive cancers when further systemic anticancer treatment is unsuitable [ID12201]	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]	Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care support	Quality standard
Clascoterone for treating acne vulgaris in people 12 years and over [TSID12136]	Technology appraisal guidance